Livestock farming accounts for approximately 70–80% of global antibiotic consumption by mass. Antibiotics are used therapeutically (treating sick animals), prophylactically (preventing disease in at-risk groups), and metaphylactically (treating groups when some members show signs of infection). Growth-promotion use — administering sub-therapeutic antibiotics to accelerate weight gain — has been banned in the EU since 2006 and globally restricted in many jurisdictions, but persists in some markets.
The link between livestock antibiotic use and antimicrobial resistance (AMR) in human pathogens is scientifically established. AMR is projected to cause 10 million human deaths annually by 2050 (O'Neill Review). Livestock represent both a reservoir of resistance genes and a pathway for resistant bacteria to reach humans through the food chain, environment, and direct contact.
The EU Veterinary Medicinal Products Regulation (2019/6), fully effective from January 2022, prohibits prophylactic group treatments (except in exceptional circumstances), restricts metaphylactic use to cases where veterinary examination confirms high risk, and bans the use of critically important antibiotics (CIAs) for growth promotion. EU reporting under the ESVAC system shows a 47% reduction in veterinary antibiotic sales from 2011–2022. Denmark, Netherlands, and Germany have the lowest use rates per livestock unit in the EU.
The 2025 EU review of the regulation found compliance generally strong, with continued declining trends, but flagged concerns about increased prophylactic use in some third countries supplying animal products to the EU market.
The FDA Veterinary Feed Directive (VFD, 2017) eliminated over-the-counter sales of medically important antibiotics for livestock and required veterinary authorization. The 2023 FDA Guidance #263 eliminated the routine use of medically important antibiotics for disease prevention without veterinary oversight. USDA's 2025 Animal Drug User Fee Act reauthorization included enhanced monitoring requirements for antibiotic sales disaggregated by species and use category.
Despite these advances, the US remains among the highest per-animal antibiotic users in the developed world. Industry self-reporting indicates prophylactic use continues in poultry and swine sectors. Major retail chains including Walmart, McDonald's, and Costco have set supply chain targets for reduced antibiotic use that are driving faster change in some sectors than regulation alone.
China is the world's largest user of veterinary antibiotics by volume. The 2020 ban on colistin as a growth promoter — following discovery of transferable colistin resistance (mcr-1 gene) — was a landmark. Further restrictions implemented in 2023 required prescription-only sales for all medically important antibiotics. Chinese veterinary antibiotic sales data shows a 38% reduction from 2015–2023, though enforcement in rural areas remains inconsistent. China's 2025–2030 National Action Plan on AMR includes specific livestock stewardship targets with provincial performance assessments.
The AMR burden from livestock is increasingly concentrated in rapidly intensifying livestock sectors in LMICs. India, Brazil, and several Southeast Asian countries have high and growing veterinary antibiotic use. WHO's Global Action Plan on AMR supports country-level stewardship programs. The Fleming Fund, FAO, and World Bank are investing in veterinary AMR surveillance capacity in 24 target countries. Challenges include weak veterinary regulatory systems, over-the-counter antibiotic availability, and limited farmer awareness.
Reducing antibiotic use without harming animal welfare requires that animals be healthier and better managed — not simply that sick animals go untreated. The "responsible reduction" model, promoted by the British Veterinary Association and the OIE, holds that welfare and stewardship are complementary: healthy animals need fewer antibiotics, and farms with better management, biosecurity, and housing conditions achieve lower use naturally.
However, irresponsible reduction — driven purely by cost-cutting or label demands — can cause welfare harm. The UK's rapid shift away from antibiotics in poultry production was initially associated with increased mortality from necrotic enteritis and other diseases. Welfare safeguards require that reduced antibiotic use is accompanied by improved husbandry, vaccination programs, and access to veterinary care.
Vaccines are the most important alternative to prophylactic antibiotics. Effective vaccines reduce disease incidence and thus antibiotic demand. The EU Swine Erysipelas vaccination program, circovirus vaccines for pigs, and Marek's disease vaccines for poultry demonstrate welfare and stewardship benefits. New veterinary vaccines in development include improved African swine fever (ASF) candidates — urgently needed as ASF drives antibiotic use in affected pig populations.
Competitive exclusion using Lactobacillus-based probiotics is effective for reducing Salmonella colonization in broiler chickens. Prebiotic fiber supplements improve gut health and reduce reliance on growth-promotion antibiotics. Research is expanding on precision probiotic formulations for different livestock species.
Phage therapy — using viruses that infect bacteria — is gaining regulatory traction for livestock. The EU approved several phage preparations for poultry Salmonella control in 2023. Clinical trials in swine show promise for controlling E. coli post-weaning diarrhea. Phage therapy is species- and pathogen-specific, requiring diagnostic infrastructure to match phages to resistant bacteria.
Biosecurity, all-in-all-out management, weaning age optimization, reduced stocking density, and improved nutrition are proven antibiotic-reduction strategies with direct welfare co-benefits. Danish pig production's "Stable Schools" peer learning network has shared management improvements that reduced antibiotic use by 50% in participating farms while improving production outcomes.
The Netherlands introduced benchmarking in 2011 — publishing farm-level antibiotic use data anonymized within peer groups, then naming farms above thresholds. This transparency-driven approach achieved a 63% reduction in Dutch veterinary antibiotic use by 2020. UK's Medicine Hub for Agriculture, Responsible Use of Medicines in Agriculture (RUMA), and VARSS reports provide sector-level benchmarks. In 2025, precision benchmarking tools using electronic medicine recording apps are enabling real-time stewardship monitoring in the UK, Netherlands, and Denmark.
The WHO list of Critically Important Antibiotics (CIAs) — carbapenems, 3rd/4th generation cephalosporins, fluoroquinolones, polymyxins, and glycopeptides — are highest priority for restriction in livestock. Colistin (a polymyxin) has been largely withdrawn from livestock use in Europe. Fluoroquinolone use restrictions are tightening across the EU and increasingly globally. Third-generation cephalosporins are restricted in poultry production in the EU. In 2025, WHO issued updated guidance recommending complete prohibition of CIAs for all livestock uses except therapeutic treatment of individual animals.
Tags: Antibiotics AMR Livestock Stewardship Welfare 2025